

THE BIOFILM COMPANY

KANE
BIOTECH

Investor Update

What the Sale of STEM Animal Health Means for Kane Going Forward

TSX-V:KNE

OTCQB:KNBIF

April - 2024

Cautionary Note

Regarding Forward-Looking Statements

This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions.

Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

Kane Biotech is THE Biofilm Company

Leading the advancement of technologies and products that break up biofilms and destroy bacteria *on skin.*



Dr. Robert Huizinga
Executive Chair

Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and led the clinical development of voclosporin which had first year sales of \$100 million USD. Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc. (TSV:ISA), and was a clinical investigator at the University of Alberta.



Marc Edwards
President, CEO, Director

Mr. Edwards was appointed as the President and CEO of the Corporation on September 10, 2018. He is the founder and President of VétRx Inc., a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. He also co-founded and was vice president of Oxygen Corporate Health from 2003 to 2008 which was later acquired by CGI Inc.



Ray Dupuis
Chief Financial Officer

Ray Dupuis joined Kane Biotech as Chief Financial Officer in September 2017. Mr. Dupuis has more than 25 years of financial leadership experience across a broad range of industries including 15 years at a rapidly growing public biotechnology company and brings to the organization considerable financial acumen and strategic skills.



Wendy Nachtigall
Director, Marketing

Wendy Nachtigall joined Kane Biotech in October 2015 as Director, Retail. With 15+ years in the marketing communications industry, Ms. Nachtigall brings a wealth of knowledge and expertise in planning, implementing and evaluating strategic marketing and communications initiatives in the consumer, institutional and B2B sectors, including new product and service introductions, brand development strategies and growth of business.



Lori Christofalos
VP, Quality & Compliance


Lori Christofalos joined Kane Biotech as VP, Quality & Compliance in August 2019. Ms. Christofalos has over 25 years of leadership experience in Quality, Compliance, Validation and Regulatory Affairs in regulated Pharma industry in both domestic and international domains. In addition to this she brings to the organization extensive knowledge of Strategic Planning and process development.



The Impact of Biofilms

Biofilms are a glue-like substance excreted by bacteria and/or fungi to attach to surfaces

- **Biofilms** protect and allow bacteria to survive and thrive in hostile environments.
- **Biofilms** make bacteria up to 1,000 times more resistant to antibiotics and antimicrobials.
- **Biofilms** are one of the main contributors to antibiotic resistance. The NIH estimates that 80% of all known human infections are associated with biofilms.



Biofilm impaired healing is the largest unresolved problem in **Wound Care**

Studies have reported a prevalence of biofilms in over 78% of chronic wounds. The Centers for Disease Control and Prevention (CDC) has identified resistant bacteria, which biofilms are a major contributor, as being a serious and urgent clinical and financial burden to health care systems and patients. Antibiotic resistance (AR) is predicted to be the next global pandemic.

\$20 MARKET SIZE
BILLION+ USD



Biofilms and link to **Dermatology**

Recent research has indicated that the persistence of microbial biofilms may be linked to aggravating symptoms associated with common skin conditions including dandruff, seborrheic dermatitis, and acne (which affects 40 to 50 million Americans).

\$15 MARKET SIZE
BILLION+ USD

Kane Biotech Technologies

Setting a New Standard in Biofilm Treatment

KANE
BIOTECH



coactiv+™

Derived From GRAS Ingredients

Kane Biotech's patented coactiv+™ technology is specifically formulated to destabilize biofilm with demonstrated efficacy and safety through animal oral care clinical trials and two human consumer trials on its DermaKB™ Shampoo.

- Technology used in animal care & human health industries
- Effective against bacterial and fungal biofilms
- Efficacy and safety demonstrated through two pet oral care clinical trials and two human shampoo consumer trials
- Simple regulatory path, combination of GRAS (generally regarded as safe) ingredients

**Prolonged
activity**

DispersinB®

A Naturally Occurring Enzyme

Kane Biotech's patented, antibiofilm DispersinB® technology has demonstrated efficacy, safety, and stability both in vitro and in vivo. DispersinB® is the only enzyme that specifically targets the biofilm framework, destroying the biofilm exopolymeric matrix from the inside.

- Disruptive technology, very fast acting
- Effective against PNAG biofilms (approx. 75% of bacteria)
- Efficacy and safety demonstrated through scientific research papers
- No identified competitors

**Fast
Acting**

STEM Animal Health – Transaction Details



+ Dechra Veterinary Pharmaceutical acquiring 100% of STEM for \$12.5M USD

- Demonstrates the high value of Kane's technology portfolio

+ Kane will receive:

- \$8M USD (\$10,900,000 CDN)
- Cash Free Debt Free Transaction
 - \$1M CDN working capital received
- \$750K USD 1-time milestone payment
- Product Development Agreement
- Transitional Manufacturing Agreement



Transaction will ultimately net Kane over \$13M CDN



Antimicrobial Wound Gel

- FDA 510(k) cleared – Q2-2023
- US distribution agreement (ProgenaCare) signed Q2-2023

DispersinB®

Wound Gel

- Development funded by the US Department of Defence
- Clinical Trial Beginning 1H-2024

DermaKB


Therapeutic Shampoo and Scalp Detoxifier

- Compelling results from large consumer trial
- Commercializing online as we explore potential licensing partners.

DispersinB®

Skin Cleanser

- Acne clinical trial at the University of Miami 2H-2024



revvyve™
ANTIMICROBIAL WOUND GEL



A Fresh Start for Chronic Wounds

The hydrogel dressing market in the U.S. is estimated at USD \$258 million in 2022.

EFFICACY
EASE OF USE
ACCESSIBILITY



U.S. FDA 510(k) clearance obtained May 2023

revyve™ Antimicrobial Wound Gel

> EFFICACY

- A unique, synergistic combination of Kane Biotech's patented coactiv+ technology with PHMB
- Prolonged inhibition of biofilm formation as well as dispersion of mature biofilms up to 7 days
- Inhibition of both metalloproteases (MMPs, TACE) as well as serine proteases (neutrophil elastase)

> EASE OF USE

- A non-ionic pluronic surfactant creates a clear gel with thermo-sensitive properties
- Gels at higher temperatures and liquifies at lower temperatures (below 60°F) making it ideal for sensitive wounds such as burns
- Easy to apply, stays on the wound and rinses easily with water

> ACCESSIBILITY

- Very attractive COGS allows for a market price below current reimbursement parameters
- Under surgical dressing policy (A6248), US \$19.88/oz with US \$59.64/3 oz the monthly allowable
- Only premium gel at a price point fully covered by public and private insurers

Thermo-Gelling Process

revvyve™
ANTIMICROBIAL WOUND GEL

**REVVYVE™
ANTIMICROBIAL WOUND
GEL LIQUIFIES AT
TEMPERATURES
BELOW 60°F**

New revyve™ Bag-on-Valve Spray

- Leverages existing FDA Clearance
- New propellant-free, bag-on-valve application system allows revyve™ Antimicrobial Wound Gel to be easily sprayed on the burn or sensitive wound
- Thermo-reversible properties make revyve™ easy to rinse off with cool water
- Eliminates any direct physical contact with the burn wound reducing risk of infection and pain
- Patent-pending




Controlled Spray Application

- The non-propellant spray formulation is delivered in a sufficiently wide, yet targeted and homogenously-distributed spray pattern
- Thermo-reversible formulation allows gel to adhere to the skin upon application to effectively start working on the wound




Spray Application



Distribution Agreements

- 1 On-going discussions
- 2 MDSAP opens these markets
- 3 Seeking strategic partner




DermaKB™

Commercializing online as we explore potential licensing partners.


Successful DermaKB™ Shampoo and Scalp Detoxifier trials with over 4,000 participants



Average of 82% of Participants Saw an Improvement in Their Symptoms Using Both Detoxifier + Shampoo in Consumer Trial



Average of 33% Reduction in Severity of Symptom After Using Either Shampoo or Detoxifier




Setting a New Standard in Biofilm Treatment

DispersinB[®] has demonstrated efficacy, safety, and stability both *in vitro* and *in vivo*.

DispersinB[®] is the only enzyme that specifically targets the biofilm framework, destroying the biofilm exopolymeric matrix from the inside.

- Fast acting disruptive technology
- Effective against PNAG (poly-N-acetylglucosamine) biofilms
- No identified biofilm competitors

DispersinB[®]



DispersinB[®] dissolving PNAG polysaccharides, thus eliminating the biofilm matrix (in minutes)


- + THE Missing Link in Wound Care.**
 - Pursuing PMA Pathway - Allow for DispersinB[®] to become the first product to receive biofilm related claims and obtain a new reimbursement code for a higher price point
 - DOD Funded - USD \$2.7M in non-dilutive funding from the U.S. Department of Defense based on Medical Technology Enterprise Consortium (MTEC) Research Project Award
- + Significantly Accelerated Healing of Wounds Compared to Controls in Pre-Clinical Trials**
 - Extensive pre-clinical testing conducted at Charles-River Laboratories. Passed all safety and biocompatibility tests
 - In 2022, awarded an additional USD \$425k of funding based on positive results from extensive safety and biocompatibility pre-clinical work
- + GMP Manufactured Product**
 - Scale up manufacturing completed at DDL
- + Clinical Trial Beginning in H1 2024**
 - 9-month, 75 patient safety trial – first of two



How Biofilms Lead to Acne

- *S. epidermidis* forms aerobic biofilm at the opening of the hair follicle that consumes O_2
- The concentrations of O_2 decreases in deeper levels into the hair follicle
- Low O_2 concentrations in the lower regions of hair follicles allow the facultative anaerobe bacteria, *C. acnes*, to proliferate and eventually form a biofilm
- Approx. 80% of combined biofilms synthesized comprise PNAG polysaccharides which contribute to the formation of the follicular (sebum) plug in acne lesions, and provide the tolerance of bacteria from antibiotics, antimicrobials and host immunity
- Chronic inflammation develops the acne dermatological pathology


Biofilm model of acne
follicular anaerobiosis



Acne Clinical Trial:



- University of Miami Clinical Trial 1H2024
 - Testing DispersinB® Wound Gel as a skin cleanser on Acne patients
 - 20 patients – Half face with DispersinB® wound gel, followed by entire face with benzoyl peroxide
 - Leverages the safety and biocompatibility studies already completed for DispersinB® Wound Gel
-
- Acne is a significant problem for millions of people with the global acne treatment market determined at USD \$9.36 billion in 2022, despite the fact there has been little to no novel treatments developed in the last 50 years
 - There is growing evidence acne is particularly difficult to solve because of biofilms
 - Kane believes their DispersinB® enzyme could be the missing link in preventing and treating lesions



Conclusion

The sale of STEM Animal Health allows Kane to significantly strengthen its balance sheet and narrow its focus on human health biofilm solutions:



coactiv+™ Antimicrobial Wound Gel

- FDA 510(k) clearance obtained – Q2-2023
- US distribution agreement (ProgenaCare) signed Q2-2023



DispersinB® Wound Gel

- Development funded by the US Department of Defence
- Clinical Trial Beginning 1H- 2024



DispersinB® Skin Cleanser

- Acne clinical trial at the University of Miami 2H-2024



DermaKB™ therapeutic shampoo

- Proven efficacy in massive consumer trial
- Commercializing online as we explore potential licensing partners

Share Summary

Listing: TSX-V:KNE, OTCQB:KNBIF

Stock Price: \$0.14

52 Week Range: \$0.05-0.17

Market Cap: \$17M



Contact Information:

Marc Edwards, Chief Executive Officer

medwards@kanebiotech.com

C: (514) 910-6991

Ray Dupuis, Chief Financial Officer

rdupuis@kanebiotech.com

C: (204) 298-2200

KANEBIOTECH.COM